Rubella vaccine

Rubella vaccine is a vaccine used to prevent rubella. Effectiveness begins about two weeks after a single dose and around 95% of people become immune. Countries with high rates of immunization no longer see cases of rubella or congenital rubella syndrome. When there is a low level of childhood immunization in a population it is possible for rates of congenital rubella to increase as more women make it to child-bearing age without either vaccination or exposure to the disease. Therefore, it is important for more than 80% of people to be vaccinated. By introducing rubella containing vaccines, rubella has been eradicated in 81 nations, as of mid-2020. The World Health Organization (WHO) recommends that the rubella vaccine be included in routine vaccinations. If not all people are immunized then at least women of childbearing age should be immunized. It should not be given to those who are pregnant or those with very poor immune function. While one dose is often all that is required for lifelong protection, often two doses are given. Side effects are generally mild. They may include fever, rash, and pain and redness at the site of injection. Joint pain may be reported at between one and three weeks following vaccination in women. Severe allergies are rare. The rubella vaccine is a live attenuated vaccine. It is available either by itself or in combination with other vaccines. Combinations include with measles (MR vaccine), measles and mumps vaccine (MMR vaccine) and measles, mumps and varicella vaccine (MMRV vaccine). A rubella vaccine was first licensed in 1969. It is on the World Health Organization's List of Essential Medicines. , more than 173 countries included it in their routine vaccinations. Rubella vaccine is on the World Health Organization's List of Essential Medicines. There are two main ways to deliver the rubella vaccine. The first is initially efforts to immunize all people less than forty years old followed by providing a first dose of vaccine between 9 and 12 months of age.

About this result

This page is automatically generated and may contain information that is not correct, complete, up-to-date, or relevant to your search query. The same applies to every other page on this website. Please make sure to verify the information with EPFL's official sources.

Related publications (5)

Related concepts (4)

Related lectures (4)

Measles vaccine

Measles vaccine protects against becoming infected with measles. Nearly all of those who do not develop immunity after a single dose develop it after a second dose. When rate of vaccination within a population is greater than 92%, outbreaks of measles typically no longer occur; however, they may occur again if the rate of vaccination decrease. The vaccine's effectiveness lasts many years. It is unclear if it becomes less effective over time. The vaccine may also protect against measles if given within a couple of days after exposure to measles.

Rubella

Rubella, also known as German measles or three-day measles, is an infection caused by the rubella virus. This disease is often mild, with half of people not realizing that they are infected. A rash may start around two weeks after exposure and last for three days. It usually starts on the face and spreads to the rest of the body. The rash is sometimes itchy and is not as bright as that of measles. Swollen lymph nodes are common and may last a few weeks. A fever, sore throat, and fatigue may also occur.

Mumps

Mumps is a viral disease caused by the mumps virus that is preventable with vaccination. Initial symptoms of mumps are non-specific and include fever, headache, malaise, muscle pain, and loss of appetite. These symptoms are usually followed by painful swelling of the parotid glands, called parotitis, which is the most common symptom of a mumps infection. Symptoms typically occur 16 to 18 days after exposure to the virus and resolve within two weeks. About one third of infections are asymptomatic.

High-risk human papillomavirus (HPV) are responsible for genital and oral cancers associated with the expression of the E6/E7 HPV oncogenes. Therapeutic vaccines targeting those oncogenes can only partially control tumor progression, highlighting the neces ...

BMC2019

Critical dynamics in population vaccinating behavior

Marcel Salathé, Sharada Prasanna Mohanty

Vaccine refusal can lead to renewed outbreaks of previously eliminated diseases and even delay global eradication. Vaccinating decisions exemplify a complex, coupled system where vaccinating behavior and disease dynamics influence one another. Such systems ...

National Academy of Sciences2017

The delivery of antigens on degradable nanoparticles, directly to dendritic cells residing in lymph nodes, offers great opportunities for vaccine design. This master thesis investigates the issues related to the development of vaccines based on ultrasmall ...

2008

Vaccination: From Jenner to Modern Immunization BIO-479: Immunology - advances and therapeutic implications

Explores the history, impact, and challenges of vaccination, from Jenner to modern immunization.

Design of Immunogenic Vaccines BIOENG-399: Immunoengineering

Explores the challenges and triumphs in designing immunogenic vaccines, focusing on antigens, adjuvants, and the delivery strategies for effective vaccination.

An Overview of Vaccine: Precision Tumor Recognition by T Cells BIOENG-399: Immunoengineering

Covers precision tumor recognition by T cells with combinatorial antigen-sensing circuits and the impact of vaccination on human health.